a proapoptotic function in the DNA damage response, and these functions may be independent. We propose that in response to low levels of DNA damage, the ATM-dependent prosurvival function springs into action. If this function is defective, DNA damage will accumulate activating a cell death pathway that may not involve a proapoptotic function of Bid. On the other hand, high levels of DNA damage could lead to activation of the proapoptotic function of Bid in mitochondria. In the case of hematopoietic cells, low levels of DNA damage may lead to "death by default" such that a deficiency in Bid (prosurvival function) results in hypersensitivity (as reported by Zinkel et al.) . In the case of fibroblasts and neurons, relatively high levels of DNA damage may be required to induce cell death, and so loss of Bid (proapoptotic function) results in decreased sensitivity (as reported by Kamer, Sax, Jacobs, and their colleagues). It will take more research to determine whether we are "marching" in the right direction.
Zinkel, S.S., Hurov, K.E., Ong, C., Abtahi, F.M., Gross, A., and Korsmeyer, S.J. (2005) . Cell 122, [579] [580] [581] [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] We have recently reported (Kaufmann et al., 2007) that, in contrast to two previous publications (Kamer et al., 2005; Zinkel et al., 2005) , the proapoptotic BH3-only protein Bid plays no role in DNA damage-induced or replicative stress-induced cellcycle arrest or apoptosis. Here we respond to the concerns about our study (Kaufmann et al., 2007) raised by Zinkel et al. in their Correspondence. A major criticism by Zinkel et al. is that we did not use homogeneous cell preparations or cells that were in cycle in our analyses. First, we would like to point out that most of our studies with hematopoietic cells were performed with defined cell populations (including mitogenstimulated T cells, which are in cycle) that had been sorted by flow cytometry and were therefore >95% pure. Notably, Kamer et al. (2005) in one of their experiments used primary splenocytes (Supplemental Figure  S1A) , which contain at least seven different hematopoietic cell subsets. Although these authors reported that loss of Bid protected spleen cells from DNA damage (etoposide)-induced apoptosis (Kamer et al., 2005) , we were unable to reproduce this result (Kaufmann et al., 2007) . Second, our HoxB8-immortalized growth factor (IL-3)-dependent cell lines are more homogeneous than implied by Zinkel et al., as we routinely select clones that are comparable with respect to rates of cell proliferation, morphology, and surface-marker expression. Zinkel et al. also state that the transformed mouse embryonic fibroblasts we used are not suitable for studying cellular responses to DNA damage or replicative stress, asserting that oncogenic activity may obscure possible differences caused by loss of Bid. We believe that this is unlikely because we observed no difference in DNA damage-induced or replicative stress-induced cell-cycle arrest or apoptosis between wild-type and Bid-deficient primary mouse embryonic fibroblasts (Kaufmann et al., 2007) . Moreover, Kamer et al. (2005) reported that the reduction in UV-or γ-irradiation-induced killing of cells afforded by loss of Bid was even greater (~50% difference between wild-type and bid −/− cells;
Response:
Does Bid Play a Role in the DnA Damage Response?
Cell 130, July 13, 2007 ©2007 Elsevier Inc. 11 Figure 1A ) in SV40-transformed fibroblasts than in telomeraseimmortalized fibroblasts (only ~15% difference; Figure 1A ). We found that loss of Bid had no effect on progression through the cell cycle or apoptosis in either SV40-transformed fibroblasts or E1A-Rastransformed fibroblasts (Kaufmann et al., 2007) . Given that the control of both apoptosis and passage through the cell cycle is remarkably conserved, it appears unlikely that comparatively subtle differences between cell types within a single species could explain some of the opposing results reported by the Kamer et al. (2005) and Zinkel et al. (2005) studies, that is, loss of Bid was reported to protect against DNA damage-induced apoptosis in one study but to enhance it in the other. In our view, this is a fundamental discrepancy between the two studies. Zinkel et al. comment in their Correspondence that we may not have monitored our cohorts of mice for a sufficiently long period to detect a role for Bid in tumor suppression. At present, all bid −/− mice in our observation cohort are older than 23 months, and so far the incidence of hematopoietic or other neoplasms is indistinguishable from that of wildtype mice. We agree that even longer-term followup analyses should be done to examine whether Bid can act as a tumor suppressor, but currently the evidence for this is rather weak. Loss of the BH3-only proteins Bim (Egle et al., 2004) or Puma (Hemann et al., 2004) accelerates lymphoma development in Eµ-myc transgenic mice, but loss of Bid has no impact . Homozygous mutations in Bim occur in certain human hematopoietic malignancies (Tagawa et al., 2005) , but no such defects in Bid have so far been found in any tumors.
In contrast to both the Kamer et al. (2005) and Zinkel et al. (2005) studies, we found no evidence for a significant presence of Bid in the nucleus of cells either before or after exposure to insults that induce DNA damage (Kaufmann et al., 2007) . We would like to point out that we used a widely accepted method of biochemical fractionation of cells, and that we used bid −/− cells to control for antibody specificity (Kaufmann et al., 2007) .
Finally, Zinkel et al. claim that a new study (Stracker et al., 2007) supports their conclusion that Bid is essential for apoptosis induction and cell-cycle arrest in response to DNA damage via the ability of this stress to activate ATM kinase.
Stracker et al. generated Nbs1
∆C/∆C knock-in mutant mice expressing a truncated NBS1 protein, which is unable to recruit and activate ATM and therefore incapacitates the DNA damage response pathway that leads to cell-cycle arrest and apoptosis. Thymocytes from Nbs1 ∆C/∆C mutant mice, like thymocytes lacking ATM, are abnormally resistant to apoptosis induced by γ-irradiation (Stracker et al., 2007) . Puma, which is transcriptionally activated by the tumor suppressor p53 and is the critical initiator of DNA damage-induced apoptosis (Jeffers et al., 2003; Villunger et al., 2003) , is upregulated normally in Nbs1 ∆C/∆C mutant cells, but Bid phosphorylation is abnormally reduced in these cells (Stracker et al., 2007) . If Bid is the critical downstream effector of ATM in the cellular response to DNA damage, as Gross and Zinkel propose (Kamer et al., 2005; Zinkel et al., 2005) , then bid −/− thymocytes should demonstrate the same resistance to γ-irradiation as ATM-deficient or Nbs1 ∆C/∆C mutant cells. This seems not to be the case as bid −/− thymocytes are sensitive to this treatment and other DNA damageinducing stimuli (Yin et al., 1999; Kaufmann et al., 2007) .
Our studies do not support a critical role for Bid in DNA damage-induced or replicative stress-induced apoptosis or cell-cycle arrest. We believe that the existing controversies will best be resolved by other groups performing similar and new experiments. To facilitate this, we will be making our bid −/− mice (like all of our genetically modified mice) freely available to the scientific community. 
